US-based biotechnology firm Cellistic has launched Allo Chassis, its turnkey immune-cloaked induced pluripotent stem cell (iPSC) cell line derived from CD34+ and CD4+ T-cell primary cells.
According to the company, the new cell line represents a significant advancement in the field of cell line development, reducing both timelines and costs.
Cellistic developed the Allo Chassis platform using its expertise in iPSCs, including T-cell-based treatments, under current Good Manufacturing Practice (cGMP) standards.
The company said the new cell line aligns with its strategy to enhance global access to cell therapy, leveraging the advantages of iPSCs.
Also, the Allo Chassis platform provides therapeutic developers with a new resource to shorten their development timelines while reducing costs.
With ready-to-use, immune-cloaked CD34+ and CD4+ T-cell derived iPSC lines, the new Allo Chassis cell line paves the way for faster market-ready therapies.
Cellistic founder and CTO Stefan Braam said: “Allo Chassis provides therapeutic developers with iPSC starting material featuring the most commonly used gene modifications, resulting in the deletion of HLA class I and II.
“These off-the-shelf cell lines can be efficiently customised using our STAR-CRISPR gene editing technology, enabling rapid creation of product-specific master cell banks at a significantly reduced cost.”
Cellistic will immediately start offering the Allo Chassis cell line as off-the-shelf resources, edited using its unique STAR-CRISPR gene editing technology.
The new cell line will provide its partners with access to advanced gene editing capabilities with a clear intellectual property licensing route to commercialisation.
The Allo Chassis cell banks are produced with validated workflows, superior quality control, and automation, delivering high-quality, low-passage cell lines for therapeutic use.
Cellistic will offer immune-cloaked cell banks for researchers and developers to support them with integrated, iPSC-based solutions for advanced cell therapies.
